Abstract:e17019 Background: Ataxia telangiectasia-mutated（ATM）is a serine/threonine kinase involved in DNA-damage repair (DDR) system and regulating cell cycle checkpoints, senescence, and apoptosis. Several clinical studies provide evidence about the DDR-mutated metastatic castration-resistant prostate cancer (mCRPC) benefit from PARP inhibitors (PARPi). However. the efficacy of PARPi was limited for mCRPC patients harboring ATM aberrations. We aimed to determine the association of ATM mutations with clinical and molecular features in patients with mCRPC. Methods: A total of three independent prostate cancer cohorts (MCTP, N = 61; SU2C-PCF, N = 429; MSKCC, N = 451) were used for analysis. We selected patients with characteristics “mCRPC” and “histology type: prostate adenocarcinoma”. Both the somatic and germline pathogenic alterations were analyzed, including single nucleotide variations (SNVs), in-frame insertions or deletions (Indels), frameshifts, homozygous deletions and fusions. The statistical analysis was conducted by R software (v.3.6.2). Results: We merged the three mCRPC cohorts, generating a new cohort consisting of 507 mCRPC patients. The median age was 62 (range, 38.6-89). The number of biopsies was 1-3 per patient. Of the 527 sequenced specimens, 39% were lymph node, 27% were bone, and 14% were liver. Forty percent of the patients had exposed to or on-treatment with next-generation androgen receptor signaling inhibitor (ARSI). A total of 44 patients (8.7%) harbored deleterious variations in ATM, including 10 homozygous deletions. The coexistence mutations were most commonly located in androgen receptor ( AR), followed by TTN/KMT2C/MUC16/TP53. Furthermore, we explored the association of pathogenic ATM alterations with clinical features. Compared with noncarriers of ATM mutations , carriers were diagnosed at a younger age (median: 59 vs 62.4, P = 0.022). In the subgroup from SU2C-PCF cohort, prostate specific antigen (PSA) at diagnosis and the proportion of Gleason score between 8-10 were analyzed, both showed no significant differences between the two groups. Notably, we observed a statistically significant higher TMB in ATM-altered group than ATM wildtype group (median, 2.04 vs 1.61, P = 0.013). Overall survival (OS) was not compared because of the limited clinical outcomes in ATM-mutated population. Conclusions: This study involving 3 cohorts identified the prevalence of pathogenic somatic or germline ATM mutations and explored the association of ATM alterations with both clinical and molecular features. Patients with ATM mutations tended to diagnose prostate cancer at an earlier age. Meanwhile, significantly higher TMB might imply potential immunotherapy opportunities in ATM-altered mCRPC without standard-of-care approaches.

[Role of Ataxia Telangiectasis Mutated in the Oncogenesis of Oral Squamous Cell Carcinoma].

ATM in Oral Carcinogenesis: Association with Clinicopathological Features

ATM is a Prognostic Biomarker of Survival in Head and Neck Squamous Cell Carcinoma Patients

ATM Polymorphisms Are Associated with Radiosensitivity for Patients with Esophageal Squamous Cell Carcinoma Underwent Preoperative Radiation Therapy

Expression status of ataxia-telangiectasia-mutated gene correlated with prognosis in advanced gastric cancer.

Overexpression of ATAD2 Indicates Poor Prognosis in Oral Squamous Cell Carcinoma.

P1.03-25 the Frequency and Prognosis of ATM Mutations in Chinese Non-Small-Cell Lung Cancer Patients

Discovery of a Pathogenic Variant Rs139379666 (p. P2974L) in ATM for Breast Cancer Risk in Chinese Populations

Expression of DNA Doublestrand Repair Proteins in Oral Leukoplakia and the Risk of Malignant Transformation

The landscape of ATM alteration in Chinese solid tumor patients.

Expression patterns of theATM gene in mammary tissues and their associations with breast cancer survival

Genomic and Clinicopathologic Characterization of ATM-deficient Prostate Cancer

The Expression of Ku80 and ATM in Cervical Carcinoma

Ataxia-Telangiectasia Mutated (ATM) gene signaling pathways in human cancers and their therapeutic implications

Antisense Inhibition of ATM Gene Enhances the Radiosensitivity of Head and Neck Squamous Cell Carcinoma in Mice

The Association of ATM Alterations with Clinical and Molecular Features in Metastatic Castration-Resistant Prostate Cancer.

Frequent genetic alterations and reduced expression of the Axin1 gene in oral squamous cell carcinoma: involvement in tumor progression and metastasis.

ATM May Be a Protective Factor in Endometrial Carcinogenesis with the Progesterone Pathway

ATM sequence variants associate with susceptibility to non-small cell lung cancer.

Prevalence and Characterization of ATM Germline Mutations in Chinese BRCA1/2-negative Breast Cancer Patients

Association Between ATM Rs1801516 Polymorphism and Cancer Susceptibility: a Meta-Analysis Involving 12,879 Cases and 18,054 Controls